This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Meet Dhruv, a 16-year-old patient diagnosed with JIA (extended oligoarthritis).1
'I was only 12 when they first told me that I had JIA.1'
‘My parents have tried to stay positive over the years, but I can tell they find it difficult2,3 – I’m really dependent on them’.
‘I just want to do what everyone else is doing – go out with my friends, hang out at the park – without feeling awful,4 without people feeling sorry for me’.
‘The NSAIDs and MTX just make me feel rubbish all the time.1,4 How am I going to be able to go to university or get a good job if I can’t even do basic things’?
Despite advances in JIA treatment, many children may never attain long-term remission in their adolescence.2,5,6 Only 33% of patients with JIA obtain complete remission in early adolescence.6,*
Note: This is a hypothetical case for representation purpose only.
Patients with JIA such as Dhruv moving from childhood to adolescence benefit from the long-term efficacy and safety profile of Enbrel®1,7-16
Enbrel® was the first biologic approved for more than 1 subtype of JIA.17
From the 6-year interim findings of the 2-year open-label CLIPPER study of JIA patients (eoJIA, ERA and PsA) (N=127) and its ongoing long-term extension, CLIPPER 2 (N=109).7,†
ACR and JADAS Inactive Disease Response Rates Over 72 Months7
Total population, n=127
Adapted from Foeldvari I, et al. 2019.
Please consult the LPD for contraindications, warnings, precautions and other important safety information.
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.
*From a prospective cohort study of 434 patients diagnosed with JIA between 1997 and 2000 in Denmark, Norway, Sweden and Finland. Results are based on outcomes of 329 patients who attended a clinical follow-up visit approximately 18 years after disease onset. Complete remission was defined as remission for at least 12 months off medication.4
†From the 6-year interim findings of the 2-year open-label CLIPPER study of patients with JIA (eoJIA, ERA, PsA) (N=127) and its ongoing long-term extension, CLIPPER2 (N=109).7
Study design: Foeldvari I, et al. 2019.
CLIPPER was a 2-year open-label study that assessed the efficacy and safety of Enbrel® in paediatric patients with eoJIA, ERA and PsA. Patients who received at least 1 dose of Enbrel® and who completed approximately 2 years of CLIPPER were eligible to enter CLIPPER 2, which is an ongoing, 8-year, long-term extension study.7
The primary endpoint of CLIPPER was the percentage of patients achieving ACR30 response at Week 12.8 Efficacy endpoints assessed to date (24 months of CLIPPER and 48 months of CLIPPER 2) included the JIA core set of measures, the JIA ACR response criteria and the JADAS.8 Safety assessments included TEAEs.7
‡From the JuMBO registry, which followed 346 patients with JIA formerly included in the BiKeR registry into adolescence. Both physician- (clinical status, AEs) and patient- (functional capacity, HRQoL) reported outcomes were recorded.12
§From observation of Enbrel® safety in JIA patients enrolled in BiKeR and JuMBO, most of whom were prospectively followed for more than 5 years.13,14
ACR, American College of Rheumatology; AE, adverse event; BiKeR, German Biologics JIA Registry; CLIPPER, CLinical Study In Pediatric Patients of Etanercept for Treatment of ERA; eoJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; HRQoL, health-related quality of life; ISR, injection site reaction; JADAS, Juvenile Arthritis Disease Activity Score; JIA, juvenile idiopathic arthritis; JuMBO, Juvenile arthritis MTX/Biologics long-term Observation; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; pJIA, polyarticular juvenile idiopathic arthritis; poJIA, persistent oligoarticular juvenile idiopathic arthritis; PRO, patient-reported outcome; PsA, psoriatic arthritis; RF+, rheumatoid factor positive; RF−, rheumatoid factor negative; sJIA, systemic juvenile idiopathic arthritis; SmPC, summary of product characteristics; TEAE, treatment-emergent adverse event.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.